The intense intrinsic fluorescence emissions from several clinically r
elevant camptothecin drugs have been exploited in order to determine (
1) the structural basis of drug binding to lipid bilayers, (2) the lip
id bilayer stability of each drug's alpha-hydroxylactone moiety, a pha
rmacophore which is essential for antitumor activity, and (3) the site
of drug binding in the bilayer. Equilibrium affinities of camptotheci
n and related congeners for small unilamellar vesicles composed of ele
ctroneutral dimyristoylphosphatidylcholine (DMPC) or negatively-charge
d dimyristoylphosphatidylglycerol (DMPG) were determined using the met
hod of fluorescence anisotropy titration. Experiments were conducted i
n phosphate-buffered saline (PBS) at 37-degrees-C and overall associat
ion constants (K values) were determined. Of the seven compounds studi
ed, the new compound 9-chloro-10,11-methylenedioxy-(20S)-camptothecin
(CMC) was found to display the highest membrane affinities (K(DMPC) =
400 M-1, K(DMPG) = 320 M-1), followed by 10,11-methylenedioxycamptothe
cin and camptothecin, which exhibited K(DMPC) and K(DMPG) values of 10
0 M-1 or greater. Topotecan displayed markedly reduced binding to lipi
d bilayers (K(DMPC) = 10 M-1, K(DMPG) = 50 M-1). HPLC assays were subs
equently employed to assess the relative stabilities of the lactone ri
ng of membrane-bound drugs. Our results clearly indicate that lipid bi
layer interactions stabilize the lactone moiety of camptothecin drugs.
In comparison to half-lives in PBS (37-degrees-C) of 17 and 19 min fo
r camptothecin and CMC, respectively, DMPC- or DMPG-bound drugs were f
ound to be stable even for periods up to 72 h. Iodide quenching data i
ndicate that membrane-bound camptothecin intercalates between the lipi
d acyl chains, in a protected environment well removed from the aqueou
s interface. In this manner lipid bilayer interactions stabilize the l
actone ring structure of camptothecins and thereby conserve the biolog
ically active form of each medication.